Final-Program-ATS-2023-AP.vp

282

TUESDAY • MAY 23

12:24 The Airborne Hazards and Open Burn Pit Registry M.J. Falvo, PhD, East Orange, NJ 12:36 Impact of the PACT Act for VA and non-VA Providers P. Hastings, DO, Washington, DC 12:50 Summary and Question/Answer Session P.D. Blanc, MD, San Francisco, CA

NIAID SYSTEMS BIOLOGY OF ANTIMICROBIAL RESISTANCE OUTSIDE ORGANIZATION SESSION

L20 SYSTEMS BIOLOGY FOR ACUTE RESPIRATORY INFECTIONS 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 145 A-B (Street Level) Target Audience Basic and translational researchers interested in a systems biology approach to lung pathogens and the host response to them. Objectives At the conclusion of this session, the participant will be able to: • apply a systems biology approach to studying clinical infectious disease outcomes • define strategies to improve ability to model lung immunity • be aware of NIH resources for studies of host immunity and microbial pathogenesis The NIH/NIAID uses a variety of mechanisms to support research on respiratory infections, including influenza, SARS-CoV-2, fungi, and antibiotic resistant bacterial pathogens. A systems biology approach to these pathogens, resultant host response, and diseases relevant to the pulmonary and critical care community will be illustrated. Chairing: L. Brown, PhD, Rockville, MD 12:00 NAIAD’s Systems Biology Program in Infectious Diseases R. Shabman, PhD, Rockville, MD 12:15 Influenza Viral-Host Interactions A. Garcia-Sastre, PhD, New York, NY 12:35 Host-Pathogen Relationship in Severe Pneumonia R.G. Wunderink, MD, Chicago, IL 12:55 Questions and Panel Discussion L. Brown, PhD, Rockville, MD

DIVISION OF LUNG DISEASES, NHLBI/NIH OUTSIDE ORGANIZATION SESSION

L19 NHLBI PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY (PETAL) NETWORK 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 204 A-C (Level 2) Target Audience Practicing critical care and emergency medicine clinicians and clinical researchers would benefit from this session Objectives At the conclusion of this session, the participant will be able to: • understand the goals and structure of the PETAL network • understand the questions being addressed in PETAL and the design/conducts of the studies • learn new findings and results of PETAL studies This session will provide an update on the NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) clinical trials network. The session will describe the structure and goals of the PETAL network, an overview of progress in ongoing studies, opportunities for additional studies using PETAL data and biospecimens, and results of studies to date. Chairing: J.P. Kiley, Ph.D., Bethesda, MD R.G. Brower, MD, Baltimore, MD 12:00 PETAL Overview R.G. Brower, MD, Baltimore, MD 12:12 Update on the CLOVERS trial I.S. Douglas, MD, FRCP, Denver, CO 12:24 Update on the ASTER trial M.A. Matthay, MD, San Francisco, CA 12:36 Update on the CORAL Studies C.T. Hough, MD, MSc, Portland, OR 12:48 Accessing PETAL Data, Images, and Specimens I.D. Peltan, MD, MSc, Murray, UT

DIVISION OF LUNG DISEASES, NHLBI/NIH OUTSIDE ORGANIZATION SESSION

L21 NEW FINDINGS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD II (SPIROMICS II) STUDY 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 143 A-C (Street Level)

ATS 2023 • Washington, DC